LDL

Introduction

Introduction to LDL and Lipoproteins

Low-density lipoproteins (LDL) are a class of lipoproteins that transport cholesterol and triglycerides in the bloodstream. They play a central role in lipid metabolism and are critical for delivering cholesterol to peripheral tissues. However, elevated LDL levels are strongly associated with atherosclerosis and cardiovascular disease, making their biochemistry a key focus in preventive medicine and pharmacology.

Role of Lipoproteins in Lipid Transport

Lipoproteins are macromolecular complexes composed of lipids and apolipoproteins that solubilize and transport hydrophobic lipids through the aqueous bloodstream. They are classified by density and size into chylomicrons, very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), LDL, and high-density lipoproteins (HDL). Each class has distinct functions, origins, and metabolic fates, with LDL serving as the primary carrier of cholesterol to cells.

Study

Structure and Composition of LDL

LDL particles are approximately 20–25 nm in diameter and consist of a hydrophobic core containing cholesteryl esters and triglycerides, surrounded by a monolayer of phospholipids and free cholesterol. The major apolipoprotein in LDL is apoB-100, a large protein that mediates binding to the LDL receptor. The surface composition and size of LDL particles influence their atherogenic potential, with smaller, denser LDL being more prone to oxidation and endothelial penetration.

Biosynthesis and Metabolic Pathway of LDL

LDL is derived from VLDL metabolism in the circulation. VLDL is synthesized in the liver and secreted into the bloodstream, where it undergoes lipolysis by lipoprotein lipase (LPL), releasing free fatty acids and forming IDL. IDL can either be taken up by the liver via the LDL receptor or further metabolized into LDL by hepatic lipase. This process ensures the delivery of cholesterol to peripheral tissues while maintaining lipid homeostasis.

LDL Receptor-Mediated Endocytosis

The LDL receptor (LDLR) is a cell-surface glycoprotein that binds apoB-100 on LDL particles, initiating receptor-mediated endocytosis. Once internalized, LDL is delivered to lysosomes, where cholesteryl esters are hydrolyzed to free cholesterol. This cholesterol regulates cellular cholesterol synthesis via inhibition of HMG-CoA reductase and suppresses LDLR expression through sterol regulatory element-binding proteins (SREBPs), providing feedback control of cholesterol uptake.

Pathophysiological Role of LDL in Atherosclerosis

Elevated LDL levels promote atherosclerosis by infiltrating the arterial intima, where they undergo oxidation. Oxidized LDL (oxLDL) is taken up by macrophages via scavenger receptors, leading to foam cell formation and the development of fatty streaks. These processes trigger inflammatory responses, smooth muscle cell proliferation, and plaque formation, ultimately contributing to cardiovascular events such as myocardial infarction and stroke.

Regulation of LDL Levels and Therapeutic Targets

LDL levels are regulated by genetic and environmental factors, including diet, physical activity, and medications. Statins, the cornerstone of LDL-lowering therapy, inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDLR expression. Other therapies, such as PCSK9 inhibitors, enhance LDLR recycling, while ezetimibe blocks intestinal cholesterol absorption. These interventions collectively reduce LDL levels and cardiovascular risk.

Summary

Key Takeaways

LDL is a critical lipoprotein in cholesterol transport, derived from VLDL metabolism and primarily cleared via LDL receptor-mediated endocytosis. Its structure, metabolism, and regulation are central to lipid homeostasis, while its dysregulation contributes to atherosclerosis. Understanding LDL biochemistry is essential for developing and applying lipid-lowering therapies in clinical practice.

Clinical Correlate

Elevated LDL cholesterol is a major modifiable risk factor for atherosclerotic cardiovascular disease. Measurement of LDL levels is a standard component of cardiovascular risk assessment, and therapeutic interventions targeting LDL reduction—such as statins, PCSK9 inhibitors, and lifestyle modifications—have been shown to significantly reduce morbidity and mortality in high-risk patients.